The CDC was expected last month to publish a study showing that Covid vaccines reduced the likelihood of severe illness, but ...
I initiate coverage on Forte Biosciences stock at a 'Hold' rating due to both pipeline risk and upcoming clinical catalysts.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results